A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

Sponsor:

BMT CTN

Sponsor Study ID:

2203/INCB 18424-370

CTO #:

104014

NCT Number:

NCT06615050

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Myeloid and Monocytic Leukemia; Non-Hodgkin's Lymphoma; Other Hematopoietic

Study Objectives:

The primary objective of the Phase Ill portion of the trial is to compare GVHD-free survival (GFS) up to 24 months after hematopoietic cell transplantation (HCT) between the two GVHD prophylaxis regimens. An event for this time-to-event outcome is defined as Grade Ill-IV acute GVHD, chronic GVHD requiring systemic immune suppression, or death by any cause.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)